Milestone Scientific Inc. (MLSS)
| Previous Close | 0.5701 |
| Open | 0.6100 |
| Bid | 0.0000 x 1400 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.5600 - 0.6100 |
| 52 Week Range | 0.5200 - 1.3500 |
| Volume | |
| Avg. Volume | 75,348 |
| Market Cap | 43.77M |
| Beta (5Y Monthly) | 0.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1000 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
GlobeNewswireMilestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida
PRC Alliance Pain Relief Center operates 8 locations across central Florida Dr. Bakshi reports 100% success performing Epidural Steroid Injection (ESI) procedures during evaluation period ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into PRC Alliance Pain Relief Center
- GlobeNewswire
Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023
Reports acceleration of reimbursement claims submission for the CompuFlo® Epidural System TechnologyROSELAND, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and announces financial results for the year ending December 31, 2023. Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial
- GlobeNewswire
Milestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call
ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Monday, April 1, 2024, to discuss the company’s financial results for 2023, as well as the company’s corporate progress and other developments The conference call will be available via telephone by dialing toll free 888-50
